Alnylam Pharmaceuticals (ALNY)
(Delayed Data from NSDQ)
$143.71 USD
-0.09 (-0.06%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $143.66 -0.05 (-0.03%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth B Momentum B VGM
Price, Consensus and EPS Surprise
ALNY 143.71 -0.09(-0.06%)
Will ALNY be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ALNY based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ALNY
Zoetis (ZTS) to Report Q1 Earnings: What's in the Cards?
Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
ALNY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Alnylam Pharmaceuticals (ALNY) Stock Might be a Great Pick
Should Invesco NASDAQ Next Gen 100 ETF (QQQJ) Be on Your Investing Radar?
Pharma Stock Roundup: NVO's New Obesity Pill Data, RHHBY, AZN's Pipeline Updates
Other News for ALNY
ProQR Therapeutics nominates Maier to board of directors
First Week of December 20th Options Trading For Alnylam Pharmaceuticals (ALNY)
How Is The Market Feeling About Alnylam Pharmaceuticals?
Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results
Wolfe upgrades Ionis to outperform, cites upcoming catalysts